NCT05336565 PIM Incidence in Older Cardiovascular Patients During COVID-19 Pandemics
| NCT ID | NCT05336565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Condition | Potentially Inappropriate Medications |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2027-08-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of the study is to assess the incidence of potentially inappropriate medication (PIM) administration, polypharmacy, and potential drug-drug-interactions (PDDIs) in cardiovascular patients enrolled in the reimbursement program in the time of coronavirus disease (COVID-19) pandemic. Medical information system (MIS) "BARS" will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. The incidence rates of PIM prescriptions will be assessed in patients aged 75 years and older. Potentially inappropriate medications will be defined according to 2015 Beers criteria. Polypharmacy will be defined as being administered five or more medications at the same time. PDDIs will be checked with Medscape Drug Interaction Checker and rated as 'Contraindicated', 'Serious', and 'Requiring Monitoring'. Combined analysis of retrospective and prospective occurrences of study parameters will be performed. PIM-BARS will evaluate the incidence rates and patterns of PIM prescriptions, polypharmacy, and PDDIs in elderly cardiovascular patients enrolled in the reimbursement program in the time of COVID-19 pandemic.
Eligibility Criteria
Inclusion Criteria: * established diagnosis of cardiovascular disease * age of 18 years and older * enrollment in the reimbursement program in Tomsk Region Exclusion Criteria: * age of 17 years and younger